All In Biotech

NDA 016199 · Ani Pharms

Cortenema

Hydrocortisone · Rectal · Corticosteroid

Priority review

Last checked: Nov 19, 2026Latest source record: Jun 3, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1966

Jan 12, 1966

Approved uses

1

Original approval plus efficacy supplements

Registered trials

753

149 Phase 3, 82 recruiting

FAERS reports

68,557

56,734 serious, 10,074 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 2, 2026.

INDICATIONS AND USAGE Hydrocortisone Rectal Suspension, USP is indicated as adjunctive therapy in the treatment of ulcerative colitis, especially distal forms, including ulcerative proctitis, ulcerative proctosigmoiditis, and left-sided ulcerative colitis. It has proved useful also in some cases involving the transverse and ascending colons.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 12, 1966 Original approval · Type 3 - New Dosage Form · priority review
1 products under this application
  • CORTENEMA · HYDROCORTISONE 100MG/60ML · ENEMA, RECTAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Hydrocortisone" as an intervention, any sponsor and status, largest first.

All 753 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use9,842
  • drug ineffective7,713
  • fatigue6,120
  • condition aggravated5,620
  • nausea5,204
  • rash5,030
  • headache4,607
  • diarrhoea4,596
  • pain4,578
  • arthralgia4,418
  • dyspnoea4,405
  • pyrexia4,120

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004438
2005559
2006513
2007549
2008613
2009738
2010848
20111,086
20121,774
20131,547
20141,784
20152,446
20162,899
20173,325
20184,847
20194,344
20205,299
20215,541
20226,212
20236,140
20246,456
20256,261
20264,334

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cortenema (Hydrocortisone)

2024 spending

$8K

Beneficiaries

18

25 claims

Per beneficiary

$457

$0.36 per unit

View as table
YearSpending
2020$19,779
2021$27,113
2022$7,376
2023$6,708
2024$8,224

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,629 on PubMed

Sponsor: Ani Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.